These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2285589)

  • 1. Therapeutic potential of pure antioestrogens in the treatment of breast cancer.
    Wakeling AE
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):771-5. PubMed ID: 2285589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of antioestrogens on the proliferation of MCF-7 human breast cancer cells.
    Wakeling AE; Newboult E; Peters SW
    J Mol Endocrinol; 1989 May; 2(3):225-34. PubMed ID: 2665780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel antioestrogens without partial agonist activity.
    Wakeling AE; Bowler J
    J Steroid Biochem; 1988 Oct; 31(4B):645-53. PubMed ID: 3199810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro.
    DeFriend DJ; Anderson E; Bell J; Wilks DP; West CM; Mansel RE; Howell A
    Br J Cancer; 1994 Aug; 70(2):204-11. PubMed ID: 8054267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are breast tumours resistant to tamoxifen also resistant to pure antioestrogens?
    Wakeling AE
    J Steroid Biochem Mol Biol; 1993 Dec; 47(1-6):107-14. PubMed ID: 8274423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between novel steroid-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol- and IGF-I-induced proliferation of human breast cancer-derived cells.
    de Cupis A; Noonan D; Pirani P; Ferrera A; Clerico L; Favoni RE
    Br J Pharmacol; 1995 Nov; 116(5):2391-400. PubMed ID: 8581274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative studies on the effects of steroidal and nonsteroidal oestrogen antagonists on the proliferation of human breast cancer cells.
    Wakeling AE
    J Steroid Biochem; 1989; 34(1-6):183-8. PubMed ID: 2696844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steroidal pure antioestrogens.
    Wakeling AE; Bowler J
    J Endocrinol; 1987 Mar; 112(3):R7-10. PubMed ID: 3559447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ICI 182,780 (Fulvestrant)--the first oestrogen receptor down-regulator--current clinical data.
    Robertson JF
    Br J Cancer; 2001 Nov; 85 Suppl 2(Suppl 2):11-4. PubMed ID: 11900210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.
    Howell A; DeFriend D; Robertson J; Blamey R; Walton P
    Lancet; 1995 Jan; 345(8941):29-30. PubMed ID: 7799704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
    Lykkesfeldt AE; Madsen MW; Briand P
    Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment.
    Lykkesfeldt AE; Larsen SS; Briand P
    Int J Cancer; 1995 May; 61(4):529-34. PubMed ID: 7759159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential for a novel pure anti-oestrogen.
    Wakeling AE
    Horm Res; 1989; 32 Suppl 1():257-9; discussion 260. PubMed ID: 2613211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.
    Osborne CK; Coronado-Heinsohn EB; Hilsenbeck SG; McCue BL; Wakeling AE; McClelland RA; Manning DL; Nicholson RI
    J Natl Cancer Inst; 1995 May; 87(10):746-50. PubMed ID: 7563152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pure antiestrogen, ICI 182,780, stimulates the growth of tamoxifen-resistant KPL-1 human breast cancer cells in vivo but not in vitro.
    Kurebayashi J; Otsuki T; Yamamoto S; Kurosumi M; Nakata T; Akinaga S; Sonoo H
    Oncology; 1998 Dec; 55 Suppl 1():23-34. PubMed ID: 9852399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ICI 182,780, a new antioestrogen with clinical potential.
    Wakeling AE; Bowler J
    J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):173-7. PubMed ID: 1525058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast-cancer cells.
    Coopman P; Garcia M; Brünner N; Derocq D; Clarke R; Rochefort H
    Int J Cancer; 1994 Jan; 56(2):295-300. PubMed ID: 8314314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.
    Howell A; Robertson J
    Lancet; 1995 Apr; 345(8955):989-90. PubMed ID: 7772169
    [No Abstract]   [Full Text] [Related]  

  • 19. Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model.
    Langdon SP; Crew AJ; Ritchie AA; Muir M; Wakeling A; Smyth JF; Miller WR
    Eur J Cancer; 1994; 30A(5):682-6. PubMed ID: 8080688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen.
    Howell A; Osborne CK; Morris C; Wakeling AE
    Cancer; 2000 Aug; 89(4):817-25. PubMed ID: 10951345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.